-
公开(公告)号：US20230174647A1
公开(公告)日：2023-06-08
申请号：US17845742
申请日：2022-06-21
发明人： Xiao Min Schebye , Diana Yuhui Chen , Andrew Rankin , Xiaodi Deng , Joseph Toth , Linda Liang , Michelle Minhua Han , Christine Bee , Hong-An Truong , Mark J. Selby , Nils Lonberg , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Alan J. Korman
IPC分类号： C07K16/28 , A61K47/68 , A61P35/00 , A61K39/395 , A61K45/06 , G01N33/563 , G01N33/577
CPC分类号： C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/6803 , A61P35/00 , C07K16/2827 , G01N33/563 , G01N33/577 , A61K2039/505
摘要： The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
-
公开(公告)号：US11466092B2
公开(公告)日：2022-10-11
申请号：US16847130
申请日：2020-04-13
发明人： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC分类号： A61K39/00 , A61K39/395 , G01N33/53 , C07K16/28 , C07K16/30 , A61P35/00 , G01N33/574
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20220204618A1
公开(公告)日：2022-06-30
申请号：US17670398
申请日：2022-02-11
发明人： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US11352440B2
公开(公告)日：2022-06-07
申请号：US16117183
申请日：2018-08-30
发明人： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC分类号： A61K39/395 , C07K16/40 , C07K16/28 , C07K16/30 , G01N33/573 , A61K47/68 , A61K45/06 , G01N33/574 , A61K39/00
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US10898556B2
公开(公告)日：2021-01-26
申请号：US15946625
申请日：2018-04-05
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00 , A61P35/00
摘要： The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
-
公开(公告)号：US10653791B2
公开(公告)日：2020-05-19
申请号：US15520954
申请日：2015-11-19
发明人： Nils Lonberg , Alan J. Korman , Mark J. Selby , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Michelle Minhua Han , Ming Lei , Liang Schweizer , Sandra V. Hatcher , Arvind Rajpal
IPC分类号： C07K16/00 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/395
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
公开(公告)号：US10167343B2
公开(公告)日：2019-01-01
申请号：US15432180
申请日：2017-02-14
发明人： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Y. Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC分类号： C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573 , C07K16/28
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US10081681B2
公开(公告)日：2018-09-25
申请号：US15021102
申请日：2014-09-18
发明人： Alan J. Korman , Nils Lonberg , David J. Fontana , Andres A. Gutierrez , Mark J. Selby , Katherine E. Lewis
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , A61P35/00 , C07K16/2803 , C07K2317/21 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/94
摘要： Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
-
公开(公告)号：US09605080B2
公开(公告)日：2017-03-28
申请号：US14994828
申请日：2016-01-13
发明人： Nils Lonberg , Alan J. Korman , Bryan C. Barnhart , Aaron P. Yamniuk , Mohan Srinivasan , Karla A. Henning , Ming Lei , Emanuela Sega , Angela Goodenough , Maria N. Jure-Kunkel , Guodong Chen , John S. Sack , Richard Huang , Martin J. Corbett , Joseph E. Myers, Jr. , Liang Schweizer , Sandra V. Hatcher , Haichun Huang , Pingping Zhang
IPC分类号： C07K16/30 , C07K16/40 , A61K39/00 , A61K39/395 , A61K45/06 , G01N33/573
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3053 , C07K16/3061 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/573 , G01N2333/916
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US12129297B2
公开(公告)日：2024-10-29
申请号：US16961545
申请日：2019-01-11
发明人： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Yu-Cheng Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
CPC分类号： C07K16/2803 , A61P35/00 , G01N33/6854 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N2333/70503
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.051 秒)
